Get the Stockscreener App
2.26
0.00%
0.00
After Hours:
2.30
0.04
+1.77%
Lipocine Inc stock is traded at $2.26, with a volume of 152.31K.
It is up +0.00% in the last 24 hours and down -6.61% over the past month.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
See More
Previous Close:
$2.26
Open:
$2.31
24h Volume:
152.31K
Relative Volume:
0.40
Market Cap:
$18.63M
Revenue:
$1.98M
Net Income/Loss:
$-9.63M
P/E Ratio:
-1.2802
EPS:
-1.7653
Net Cash Flow:
$-9.76M
1W Performance:
+2.73%
1M Performance:
-6.61%
6M Performance:
-31.10%
1Y Performance:
-36.87%
1-Day Range:
$2.26
$2.38
1-Week Range:
$2.16
$2.38
52-Week Range:
$1.81
$12.37
Lipocine Inc Stock (LPCN) Company Profile
Name
Lipocine Inc
Sector
Industry
Phone
801 994 7383
Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
2.26 | 18.63M | 1.98M | -9.63M | -9.76M | -1.7653 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-06-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-12-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-11-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| Dec-08-17 | Resumed | H.C. Wainwright | Buy |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
| Jun-23-15 | Initiated | Canaccord Genuity | Buy |
View All
Lipocine Inc Stock (LPCN) Latest News
LPCN SEC FilingsLipocine Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Lipocine (LPCN) reports Q1 loss, beats revenue estimates - MSN
LPCN: Excluding an outlier site, rapid and durable efficacy with strong safety was demonstrated in PPD - TradingView
LPCN: Rapid-acting oral PPD therapy shows promise in subgroups, with funding secured for next trial - TradingView
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Pres - GuruFocus
Lipocine Announces Phase 3 Data for LPCN 1154 (Oral Brexanolone) in Postpartum Depression Selected for Oral Presentation at 2026 ASCP Annual Meeting 1 - Minichart
Lipocine’s postpartum depression drug data to be presented at ASCP By Investing.com - Investing.com South Africa
Lipocine’s postpartum depression drug data to be presented at ASCP - Investing.com UK
Lipocine Showcases Phase 3 Data for Postpartum Depression - TipRanks
Lipocine Phase 3 LPCN 1154 Data Accepted for Oral Presentation at 2026 ASCP Meeting - TradingView
Lipocine (NASDAQ: LPCN) to present LPCN 1154 Phase 3 postpartum depression data - Stock Titan
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting - The Herald Journal
Oral postpartum depression trial to be showcased at 2026 ASCP meeting - Stock Titan
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase - Sahm
Lipocine to Present Innovative Oral Therapeutics Pipeline at A.G.P.’s Annual Virtual Healthcare Showcase 2026 - Minichart
Lipocine Showcases Pipeline at Virtual Healthcare Conference - TipRanks
Lipocine to Present at A.G.P. Virtual Healthcare Showcase May 20 - TradingView
Lipocine (NASDAQ: LPCN) plans fireside chat at A.G.P. Annual Healthcare Company Showcase - Stock Titan
Ikarian Capital (LPCN) reports 508,556 shares, 6.3% ownership - Stock Titan
Squadron Master Fund LP (LPCN) reports 450,000 shares, 6.2% stake - Stock Titan
LPCN (Lipocine) Q1 loss exceeds estimates by 9.2 percent; shares unmoved as investors await updates.Stock Idea Sharing Hub - newser.com
The numbers behind Lipocine (LPCN) stock nobody talks about (Modest Decline) 2026-05-11Popular Trader Picks - Newser
A. G. P. Maintains Lipocine(LPCN.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Lipocine Inc. Announces First Quarter Financial Results Ending March 31, 2026 - geneonline.com
MSN Money - MSN
Lipocine Updates Corporate Presentation for Investor Communications - The Globe and Mail
What's going on with Lipocine stock on Monday? - MSN
Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates - sharewise.com
Lipocine Q1 net loss widens on higher R&D costs - TradingView
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 | State News | hjnews.com - The Herald Journal
Lipocine seeks FDA fast-track for PPD pill after Phase 3 miss - Stock Titan
Updated Lipocine (NASDAQ: LPCN) corporate presentation filed as Exhibit 99.1 - Stock Titan
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 - itemonline.com
Lipocine: Q1 Earnings Snapshot - Barchart.com
Lipocine Inc. 1Q 2026: Revenue $119K, EPS $(0.54) — 10-Q Summary - TradingView
PPD drug LPCN 1154 misses endpoint as Lipocine (NASDAQ: LPCN) posts Q1 loss - Stock Titan
Lipocine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lipocine (NASDAQ: LPCN) Q1 loss widens as it raises cash via ATM - Stock Titan
Lipocine Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Lipocine Inc Stock (LPCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lipocine Inc Stock (LPCN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Higuchi John W. | Director |
Apr 06 '26 |
Buy |
2.05 |
123,000 |
252,150 |
163,797 |
| Patel Mahesh V. | Chief Executive Officer |
Apr 06 '26 |
Buy |
2.03 |
25,000 |
50,750 |
160,679 |
| Patel Mahesh V. | Chief Executive Officer |
Apr 02 '26 |
Buy |
2.02 |
25,000 |
50,500 |
135,679 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):